Feed VKTX
VK

Viking Therapeutics VKTX NASDAQ · Healthcare · United States

$24.77 -4.14% -$1.07

Market cap
$3.30B
Enterprise value
$2.87B
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/FCF
-
EV/EBITDA
-
ROIC
-76.9%
Gross margin
-
Net margin
-
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.65
Free float
97.1%

About the company

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Sector

Healthcare

Industry

Biotechnology

CEO

Brian Lian

Employees

65

Headquarters

San Diego

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

  • What to watch: It missed profit estimates 7 times in the last 8 quarters.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

  • What speaks for it: It holds more cash than debt: $677.6M against $254.7M.
  • What to watch: It passes only 1 of the 9 points of the Piotroski financial health test.

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

  • What speaks for it: The price moves less than the market (beta 0.65).

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy